Single-Molecule Tethering Detects Nucleic Acids and Microorganisms
By LabMedica International staff writers Posted on 29 Oct 2020 |
Image: The signal of SMOLT is generated by the displacement of micron-size beads tethered by DNA long-probes that are between 1 and 7 microns long. The molecular extension of thousands of DNA probes is determined with sub-micron precision using a robust, rapid and low-cost optical approach (Photo courtesy of Scanogen).
Detection of microbial nucleic acids in body fluids has become the preferred method for rapid diagnosis of many infectious diseases. However, culture-based diagnostics that are time-consuming remain the gold standard approach in certain cases, such as sepsis.
The polymerase chain reaction (PCR) has enabled a revolution in in vitro diagnostics due to its sensitivity and specificity. However, polymerase-based methodologies require complex sample preparation steps to remove polymerase inhibitors in certain specimen types, and relatively expensive reagents and instrumentation.
A team of scientists at the biotechnology company Scanogen (Windsor Mill, MD, USA) collected data from 200 tests run on normal samples spiked with known concentrations of pathogen. The team used a technology called single-molecule tethering (SMOLT) that generates a signal when micron-sized beads tethered by double-stranded DNA probes inside a capillary are displaced in the presence of a target pathogen.
Beads tethered by a probe can be differentiated from beads that are not specific to the target of interest because the long-probe tethered beads are displaced by a greater distance. The displacement is determined by processing images obtained with a low-magnification lens and a low-cost digital camera.
The team reported that SMOLT technology can detect RNA molecules in whole blood, urine, and sputum. The technology also detected Candida species and two bacterial species, Staphylococcus aureus and Pseudomonas aeruginosa, in whole blood. The limits of detection was between 1 and 3 colony forming unit per milliliter (CFU/mL), comparable to current PCR tests on the market. The technology also readily lends itself to multiplexing that would enable identification of up to 20 targets per test run.
The team showed that SMOLT detection of microbial ribosomal ribonucleic acid (rRNA) enables high sensitivity with a turnaround time from sample to results of 1.5 hours. They designed species-specific probes that targeted the rRNA of the two most prevalent sepsis-causing fungi, Candida albicans and Candida glabrata, as well as pan-fungal probes that targeted highly conserved regions in fungal rRNA using a local database of microbial and human rRNA sequences.
For clinical testing in a laboratory, the company envisions that its future customers will be able to stack testing modules on top of each other. An eight-module stack, with each module running tests for up to 20 pathogens, will cost about USD 50,000, Celedon said, adding that the price is significantly lower than the instruments with which it intends to complete.
Alfredo Celedon, the founder of Scanogen and CEO, said “The firm anticipates offering pricing to laboratories at between USD 20 and USD 50 per test, while competing multiplexed tests are priced at USD 200 or more per test. For clinical testing in a laboratory, the company envisions that its future customers will be able to stack testing modules on top of each other. The study was published on September 22, 2020 in the journal Nature Communications.
Related Links:
Scanogen
The polymerase chain reaction (PCR) has enabled a revolution in in vitro diagnostics due to its sensitivity and specificity. However, polymerase-based methodologies require complex sample preparation steps to remove polymerase inhibitors in certain specimen types, and relatively expensive reagents and instrumentation.
A team of scientists at the biotechnology company Scanogen (Windsor Mill, MD, USA) collected data from 200 tests run on normal samples spiked with known concentrations of pathogen. The team used a technology called single-molecule tethering (SMOLT) that generates a signal when micron-sized beads tethered by double-stranded DNA probes inside a capillary are displaced in the presence of a target pathogen.
Beads tethered by a probe can be differentiated from beads that are not specific to the target of interest because the long-probe tethered beads are displaced by a greater distance. The displacement is determined by processing images obtained with a low-magnification lens and a low-cost digital camera.
The team reported that SMOLT technology can detect RNA molecules in whole blood, urine, and sputum. The technology also detected Candida species and two bacterial species, Staphylococcus aureus and Pseudomonas aeruginosa, in whole blood. The limits of detection was between 1 and 3 colony forming unit per milliliter (CFU/mL), comparable to current PCR tests on the market. The technology also readily lends itself to multiplexing that would enable identification of up to 20 targets per test run.
The team showed that SMOLT detection of microbial ribosomal ribonucleic acid (rRNA) enables high sensitivity with a turnaround time from sample to results of 1.5 hours. They designed species-specific probes that targeted the rRNA of the two most prevalent sepsis-causing fungi, Candida albicans and Candida glabrata, as well as pan-fungal probes that targeted highly conserved regions in fungal rRNA using a local database of microbial and human rRNA sequences.
For clinical testing in a laboratory, the company envisions that its future customers will be able to stack testing modules on top of each other. An eight-module stack, with each module running tests for up to 20 pathogens, will cost about USD 50,000, Celedon said, adding that the price is significantly lower than the instruments with which it intends to complete.
Alfredo Celedon, the founder of Scanogen and CEO, said “The firm anticipates offering pricing to laboratories at between USD 20 and USD 50 per test, while competing multiplexed tests are priced at USD 200 or more per test. For clinical testing in a laboratory, the company envisions that its future customers will be able to stack testing modules on top of each other. The study was published on September 22, 2020 in the journal Nature Communications.
Related Links:
Scanogen
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders